Dr Gregory Papagregoriou is a molecular biologist and geneticist focused on translating multi-omics discoveries into clinical applications. He directs a multidisciplinary team at biobank.cy, Center of Excellence, University of Cyprus, integrating -omics, molecular and cellular biology, nanoscience, and AI-driven modelling to advance therapeutics development in rare diseases. His work at the Broad Institute, MA, USA enabled the first clinical trial for a rare kidney disease in Cyprus. As Lead Scientist at biobank.cy he oversees its broader research portfolio, next-generation sequencing infrastructure, and Innovation Hub, while he serves in international scientific and standards committees. He coordinates ALP-RARE, an ERDERA/JTC2025 funded project.
